Ginsenoside composition with hypoglycemic activity and application thereof

A technology of ginsenosides and compositions, applied in the field of ginsenosides compositions, to achieve the effects of improving the hypoglycemic effect, reducing costs, and facilitating drug development

Inactive Publication Date: 2018-10-23
南京类人生物材料有限公司
View PDF11 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] All of the above are the pharmaceutical application of a single saponin component of ginsenoside. In the prior art, there are few reports that the composition formed by mixing different saponins of ginsenoside can improve the hypoglycemic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ginsenoside composition with hypoglycemic activity and application thereof
  • Ginsenoside composition with hypoglycemic activity and application thereof
  • Ginsenoside composition with hypoglycemic activity and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1 In vitro hypoglycemic experiment of ginsenoside monomers

[0041] Experimental drug: ginsenosides in diol group: ginsenosides Rk1, Rg3, Rg5;

[0042] Triol group ginsenosides: ginsenosides Rk3, Rh4;

[0043] The purity of the above drugs were >98%.

[0044] Experimental cells: INS-1 rat insulinoma cells, HepG2 human liver cancer cells and 3T3-L1 mouse preadipocytes were all purchased from Shanghai Bogu Biotechnology Co., Ltd., and the generations were within 10 generations.

[0045] Test method and result:

[0046] 1. Effect of ginsenoside monomers on the viability of alloxan-induced INS-1 injury model cells

[0047] After recovery, the INS-1 cells were transferred to a 100ml culture flask with RPMI 1640 culture medium containing 10% inactivated calf serum, and incubated at 37°C and 5% CO 2 cultivated under conditions. When the cells adhered to the wall and overgrown, the medium was poured out, digested with 0.25% trypsin, and passaged once every 3 days a...

Embodiment 2

[0064] Example 2 The therapeutic effect of ginsenoside monomer and drug combination on type Ⅱ diabetes mouse model

[0065] Modeling: 110 healthy male, clean C57BL / 6 mice aged 5-6 weeks (body weight 18±2 g) were purchased from the Animal Center of Xi’an Jiaotong University School of Medicine. The mice were adaptively fed for 7 days and randomly divided into two groups, one group of 10 mice was given basic feed; the other group of 100 mice was given high-fat and high-sugar feed. After 6 weeks, the high-fat and high-sugar diet group was fasted for 12 hours, and then intraperitoneally injected STZ (prepared in citrate buffer) 30 mg / kg, once a day, for 5 consecutive days to establish a diabetes model. The mice were fasted (without water) for 12 hours, and 0.2 mL of blood was collected from the fundus venous plexus of each mouse, and the serum was separated. Take 10 μL of serum in the sample tube to measure the fasting blood glucose value of the mouse according to the operation me...

Embodiment 3

[0076] Example 3 Preparation of Ginsenoside Tablets

[0077] Take 90 g of ginsenoside composition (60 g of ginsenoside Rg5 and 30 g of ginsenoside Rh4), 70 g of sodium carboxymethyl cellulose, 200 g of microcrystalline cellulose, 70 g of sodium carboxymethyl starch, and 2 g of magnesium stearate. raw material.

[0078] Pass the above-mentioned main ingredients and auxiliary materials through 80-mesh sieve respectively, mix well, use 80% ethanol as binder, granulate with 16-mesh sieve, dry at 55-60°C, granulate with 14-mesh sieve, and press into tablets, each Tablet 0.4 g.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a ginsenoside composition with hypoglycemic activity and application thereof. The ginsenoside composition consists of panaxadiol saponin and panaxatriol saponin; the panaxadiol saponin is chosen from one or two or all of ginsenoside Rk1, Rg3 and Rg5; and the panaxatriol saponin is chosen from one or all of Rk3 and Rh4. According to the invention, by combining the differenttypes of ginsenoside monomers and reasonably optimizing the proportion of the monomers, the complementary characteristic of the hypoglycemic mechanisms of all the monomers is brought into full play,and thereby the hypoglycemic effect is remarkably increased; while the hypoglycemic effect is ensured, the dosage of ginsenoside is not obviously increased, consequently, the production cost is reduced, and moreover, the biological safety of the product is also guaranteed; and compared with the hypoglycemic effects of the single ginsenoside monomers, the ginsenoside composition can better meet therequirement of new drug development in terms of efficacy, has the characteristics of high druggability and easiness in mass production, and can be more easily used in the development of patent medicine.

Description

technical field [0001] The invention belongs to the field of biochemical industry, and in particular relates to a ginsenoside composition with hypoglycemic activity and application thereof. Background technique [0002] Diabetes mellitus is a metabolic disorder syndrome related to the abnormal production and action of insulin and characterized by hyperglycemia. It is a chronic disease that seriously endangers health and is one of the major health problems facing human beings. Diabetes can be divided into insulin-dependent diabetes (type I diabetes) and non-insulin-dependent diabetes (type II diabetes), of which more than 90% are type II diabetes. With the development of social economy and the change of people's lifestyle, the number of diabetic patients is increasing rapidly. According to the latest statistics, there are about 246 million people in the world suffering from type II diabetes, and it is estimated that the number of type II diabetes patients will increase to 38...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61P3/10A23L33/10
Inventor 范代娣殷诗玉段志广傅容湛马晓轩
Owner 南京类人生物材料有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap